Entrada Therapeutics, Inc.

NASDAQ
TRDA
Stock
Yield per half year: -61.17%
Dividend yield: 0%
Sector: Healthcare

7.7 $

0 $ 0%
7.5 $
21.59 $

Min/max per year

Share chart Entrada Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.

more details
The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date
2021-10-29
ISIN
US29384C1080
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
link
All parameters

Grade

Underestimation
Title Value Grade
P/S 3.2 5
P/BV 1.57 8
P/E 10.28 9
Efficiency
Title Value Grade
ROA 13.18 4
ROE 19.56 6
ROIC 0 0
Dividends
Title Value Grade
Dividend yield 0 0
DSI 0 0
Average dividend growth 0 0
Debt
Title Value Grade
Debt/EBITDA 1.26 8
Debt/Ratio 0.1125 10
Debt/Equity 0.2278 10
Growth impulse
Title Value Grade
Yield Revenue, % 734.45 10
Yield Ebitda, % -278.75 0
Yield EPS, % -230.43 0
More

Prices

Price Min. Max. Change Changes in the industry Changes in the index
Yesterday 7.7 $ 0 $ 0 $ 0 % 0 % 0 %
Week 7.69 $ 0 $ 0 $ 0.13 % 0 % 0 %
Month 8.87 $ 7.5 $ 8.82 $ -13.19 % 0 % 0 %
Three month 12.02 $ 7.5 $ 11.22 $ -35.94 % 0 % 0 %
Half a year 19.83 $ 7.5 $ 21.52 $ -61.17 % 0 % 0 %
Year 15.39 $ 7.5 $ 21.59 $ -49.97 % 0 % 0 %
3 years 6.27 $ 7.5 $ 22.79 $ 22.81 % 0 % 0 %
5 years 0 $ 5.49 $ 35 $ 0 % 0 % 0 %
10 years 0 $ 5.49 $ 35 $ 0 % 0 % 0 %
Year to date 17.46 $ 7.5 $ 18.31 $ -55.9 % 0 % 0 %

Main owners

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Dipal Doshi CEO & Director 968.21k 1976 (49 years)
Mr. Nathan J. Dowden President & COO 694.3k 1971 (54 years)
Dr. Natarajan Sethuraman Ph.D. Chief Scientific Officer 694.3k 1962 (63 years)
Mr. Kory James Wentworth CPA CFO & Treasurer N/A 1979 (46 years)
Dr. Jared Cohen J.D., Ph.D. General Counsel N/A
Ms. Kerry Robert M.S. Senior Vice President of People N/A
Ms. Karla MacDonald Chief Corporate Affairs Officer N/A
Mr. Kevin Healy Ph.D. Senior Vice President of Regulatory Affairs N/A

About company

Address: United States, Boston. MA, 6 Tide Street - Open in google maps, Open in yandex maps
Website: https://www.entradatx.com